Publications by authors named "Elizabeth Asque"
Article Synopsis
- Alzheimer's disease (AD) is a leading cause of dementia that is fatal, and most treatments targeting amyloid beta have only limited success in slowing progression.
- Research into senescent cells (SC) and their harmful effects shows potential for new therapies, as treating aged monkeys with the senolytic drug navitoclax led to positive changes in biomarkers related to neuroinflammation and neuronal damage.
- Navitoclax was found to be safe and well tolerated in the study, suggesting its promise as a new therapeutic approach for addressing AD in humans.
Background: Alzheimer's disease (AD) is a chronic progressive neurodegenerative disease impacting an estimated 44 million adults worldwide. The causal pathology of AD (accumulation of amyloid-beta and tau), precedes hallmark symptoms of dementia by more than a decade, necessitating development of early diagnostic markers of disease onset, particularly for new drugs that aim to modify disease processes. To evaluate differentially methylated positions (DMPs) as novel blood-based biomarkers of AD, we used a subset of 653 individuals with peripheral blood (PB) samples in the Alzheimer's disease Neuroimaging Initiative (ADNI) consortium.
View Article and Find Full Text PDF